2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Landmesser, Ulf; Chapman, M. John; Stock, Jane K; Amarenco, Pierre; Belch, Jill J F; Borén, Jan; Farnier, Michel; Ference, Brian A; Gielen, Stephan; Graham, Ian; Grobbee, Diederick E; Hovingh, G. Kees; Lüscher, Thomas Felix; Piepoli, Massimo F.; Ray, Kausik K.; Stroes, Erik S G; Wiklund, Olov; Windecker, Stephan; Zamorano, Jose Luis; Pinto, Fausto; Tokgözoglu, Lale; Bax, Jeroen J.; Catapano, Alberico L.
(2018) European Heart Journal, volume 39, issue 14, pp. 1131 - 1143
(Article)
Download/Full Text
The full text of this publication is not available.
Keywords: Adult, Advisory Committees, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/therapeutic use, Anticholesteremic Agents/therapeutic use, Coronary Artery Disease/drug therapy, Female, Humans, Hyperlipoproteinemia Type II/drug therapy, Male, Middle Aged, Proprotein Convertase 9/antagonists & inhibitors, Cardiology and Cardiovascular Medicine, Research Support, Non-U.S. Gov't, Journal Article, Practice Guideline
ISSN: 0195-668X
Publisher: Oxford University Press
Note: Funding Information: Funding for travel to participate in Task Force meetings was provided by the European Atherosclerosis Society.
(Peer reviewed)